Search

Your search keyword '"Toyota, Joji"' showing total 34 results
Start Over Author "Toyota, Joji" Publication Year Range Last 10 years
34 results on '"Toyota, Joji"'

3. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection

Author

Akuta, Norio, Toyota, Joji, Karino, Yoshiyasu, Ikeda, Fusao, Ido, Akio, Tanaka, Katsuaki, Takaguchi, Koichi, Naganuma, Atsushi, Tomita, Eiichi, Chayama, Kazuaki, Fujiyama, Shigetoshi, Inada, Yukiko, Yoshiji, Hitoshi, Watanabe, Hideaki, Ishikawa, Hiroki, McPhee, Fiona, Noviello, Stephanie, and Kumada, Hiromitsu

Published
2018
Full Text
View/download PDF

4. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection

Author

Toyota, Joji, Karino, Yoshiyasu, Suzuki, Fumitaka, Ikeda, Fusao, Ido, Akio, Tanaka, Katsuaki, Takaguchi, Koichi, Naganuma, Atsushi, Tomita, Eiichi, Chayama, Kazuaki, Fujiyama, Shigetoshi, Inada, Yukiko, Yoshiji, Hitoshi, Watanabe, Hideaki, Ishikawa, Hiroki, Hu, Wenhua, McPhee, Fiona, Linaberry, Misti, Yin, Philip D., Swenson, Eugene Scott, and Kumada, Hiromitsu

Published
2017
Full Text
View/download PDF

6. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey

Author

Tokushige, Katsutoshi, Hyogo, Hideyuki, Nakajima, Tomoaki, Ono, Masafumi, Kawaguchi, Takumi, Honda, Koichi, Eguchi, Yuichiro, Nozaki, Yuichi, Kawanaka, Miwa, Tanaka, Saiyu, Imajo, Kento, Sumida, Yoshio, Kamada, Yoshihiro, Fujii, Hideki, Suzuki, Yasuaki, Kogiso, Tomomi, Karino, Yoshiyasu, Munekage, Kensuke, Kuromatsu, Ryoko, Oeda, Satoshi, Yanase, Mikio, Mori, Kohjiro, Ogawa, Yuji, Seko, Yuya, Takehara, Tetsuo, Itoh, Yoshito, Nakajima, Atsushi, Kanemasa, Kazuyuki, Nishino, Ken, Masaki, Naohiko, Takahashi, Hirokazu, Seike, Masataka, Torimura, Takuji, Saibara, Toshiji, Toyota, Joji, Chayama, Kazuaki, and Hashimoto, Etsuko

Published
2016
Full Text
View/download PDF

11. Factors affecting the recovery of hepatic reserve after sustained virologic response by direct‐acting antiviral agents in chronic hepatitis C virus‐infected patients

Author

Nakajima, Tomoaki, primary, Karino, Yoshiyasu, additional, Hige, Shuhei, additional, Suii, Hirokazu, additional, Tatsumi, Ryoji, additional, Yamaguchi, Masakatsu, additional, Arakawa, Tomohiro, additional, Kuwata, Ysuaki, additional, Hasegawa, Takashi, additional, and Toyota, Joji, additional

Published
2020
Full Text
View/download PDF

14. THU-214-Annual average of integral FIB-4 index and HBV core-related antigen as an appropriate indicators for starting nucleoside analogues at an optimum timing

Author

Hige, Shuhei, primary, Ozeki, Itaru, additional, Suii, Hirokazu, additional, Tatsumi, Ryoji, additional, Yamaguchi, Masakatsu, additional, Kimura, Mutsuumi, additional, Arakawa, Tomohiro, additional, Nakajima, Tomoaki, additional, Kuwata, Yasuaki, additional, Ohmura, Takumi, additional, Toyota, Joji, additional, and Karino, Yoshiyasu, additional

Published
2019
Full Text
View/download PDF

15. SAT-477-Impact of skeletal muscle quality and quantity on outcomes following curative therapy of hepatocellular carcinoma

Author

Nakajima, Tomoaki, primary, Suii, Hirokazu, additional, Tatsumi, Ryoji, additional, Yamaguchi, Masakatsu, additional, Kimura, Mutsuumi, additional, Arakawa, Tomohiro, additional, Kuwata, Yasuaki, additional, Ozeki, Itaru, additional, Ohmura, Takumi, additional, Hige, Shuhei, additional, Karino, Yoshiyasu, additional, and Toyota, Joji, additional

Published
2019
Full Text
View/download PDF

16. FRI-196-The development of HCC in chronic hepatitis B patients with nucleos (t)ide analogs: Focus on hepatitis B surface antigen and core-related antigen

Author

Ozeki, Itaru, primary, Suii, Hirokazu, additional, Tatsumi, Ryoji, additional, Yamaguchi, Masakatsu, additional, Kimura, Mutsuumi, additional, Arakawa, Tomohiro, additional, Nakajima, Tomoaki, additional, Kuwata, Yasuaki, additional, Ohmura, Takumi, additional, Hige, Shuhei, additional, Karino, Yoshiyasu, additional, and Toyota, Joji, additional

Published
2019
Full Text
View/download PDF

17. Factors affecting the recovery of hepatic reserve after sustained virologic response by direct‐acting antiviral agents in chronic hepatitis C virus‐infected patients.

Author

Nakajima, Tomoaki, Karino, Yoshiyasu, Hige, Shuhei, Suii, Hirokazu, Tatsumi, Ryoji, Yamaguchi, Masakatsu, Arakawa, Tomohiro, Kuwata, Ysuaki, Hasegawa, Takashi, and Toyota, Joji

Subjects
ANTIVIRAL agents, COMPUTED tomography, OLDER patients, HEPATITIS C virus, ALANINE aminotransferase
Abstract

Background and Aim: Since the advent of direct‐acting antiviral (DAA) therapy, the total eradication of hepatitis C virus has been achievable with the recovery of hepatic reserve after achievement of sustained virologic response (SVR). Hence, here, we examined the factors affecting the recovery of hepatic reserve. Methods: We followed up 403 patients (male: 164, female: 239; genotype 1: 299, genotype 2: 104; median age: 69 years) for at least 3 years after they achieved SVR to DAA therapy. Of these patients, 75 (18.6%) had a history of hepatocellular carcinoma (HCC). Biochemical tests were periodically performed, and the hepatic reserve was evaluated based on the albumin–bilirubin grade. We examined background factors such as age, biochemical test results, HCC occurrence and portosystemic shunt by computed tomography. Results: At the start of treatment, the albumin–bilirubin grades were grades 1, 2, and 3 in 241, 157, and 5 patients, respectively, and 3 years later, 117 of 162 (72%) patients with grade 2 or 3 improved to grade 1. Multivariate analysis identified the HCC occurrence after achievement of SVR (hazard ratio [HR]: 3.08, P < 0.0138), male sex (HR: 3.45, P = 0.0143), hemoglobin level of <11.5 g/dL (HR: 4.19, P = 0.0157), the presence of a portosystemic shunt (HR: 3.07, P = 0.0349), and alanine aminotransferase levels <45 U/L (HR: 2.67, P = 0.0425) as factors inhibiting improvement to grade 1. However, old age was not an inhibitory factor. Conclusion: Our results demonstrate that hepatic reserve could be improved even in elderly patients over a long course of time. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

18. Safety of Sofosbuvir and Ribavirin Combination Therapy in a Patient Who Developed Anemia due to Ribavirin

Author

Suii, Hirokazu, Ozeki, Itaru, Tatsumi, Ryoji, Yamaguchi, Masakatsu, Kimura, Mutsuumi, Arakawa, Tomohiro, Nakajima, Tomoaki, Kuwata, Yasuaki, Ohmura, Takumi, Hige, Shuhei, Karino, Yoshiyasu, and Toyota, Joji

Subjects
Article Subject
Abstract

Interferon (IFN) and ribavirin (RBV) combination therapy was previously the standard of care for treatment of hepatitis C virus (HCV) genotype 2 infection. But, it often induced hemolytic anemia. In 2014, sofosbuvir (SOF) was approved for the treatment of chronic HCV genotype 2 in Japan. SOF/RBV therapy is more effective against genotype 2 than IFN/RBV therapy. We report a case of a 74-year-old woman with chronic HCV genotype 2b infection. She received five treatments including RBV and IFN therapy before SOF was approved and all of them were ineffective. Therapies that included RBV induced severe anemia and led to discontinuation of treatment. With pegylated IFN/RBV therapy, the maximum change in hemoglobin (Hb) from baseline was −3.7 g/dL. However, SOF/RBV therapy was effective and she achieved sustained virologic response (SVR) with a maximum change in Hb from baseline of only −1.2 g/dL. We also found reticulocyte count was very low during treatment in this case and speculate it was one of the reasons that she developed hemolytic anemia with RBV. In conclusion, SOF/RBV therapy is effective and allowed the patient to achieve SVR. An SOF/RBV regimen is safe and effective for patients who have or are at risk of anemia induced by RBV.

Published
2017
Full Text
View/download PDF

19. A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3

Author

Foster, Graham R., Chayama, Kazuaki, Chuang, Wan Long, Fainboim, Hugo, Farkkila, Martti, Gadano, Adrian, Gaeta, Giovanni B., Hézode, Christophe, Inada, Yukiko, Heo, Jeong, Kumada, Hiromitsu, Sheng Nan, Lu, Marcellin, Patrick, Moreno, Christophe, Roberts, Stuart K., Strasser, Simone I., Thompson, Alexander J., Toyota, Joji, Paik, Seung Woon, Vierling, John M., Zignego, Anna Linda, Cohen, David, Mcphee, Fiona, Wind Rotolo, Megan, Srinivasan, Subasree, Hruska, Matthew, Myler, Heather, and Portsmouth, Simon D.

Subjects
virus diseases, Genotype 2, Genotype 3, Hepatitis C virus, Peginterferon alfa-2a, Peginterferon lambda-1a, Multidisciplinary
Published
2016

20. Analysis of hepatitis B surface antigen (HBsAg) using high‐sensitivity HBsAg assays in hepatitis B virus carriers in whom HBsAg seroclearance was confirmed by conventional assays

Author

Ozeki, Itaru, primary, Nakajima, Tomoaki, additional, Suii, Hirokazu, additional, Tatsumi, Ryoji, additional, Yamaguchi, Masakatsu, additional, Kimura, Mutsuumi, additional, Arakawa, Tomohiro, additional, Kuwata, Yasuaki, additional, Ohmura, Takumi, additional, Hige, Shuhei, additional, Karino, Yoshiyasu, additional, and Toyota, Joji, additional

Published
2017
Full Text
View/download PDF

21. Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens

Author

Reddy, K. Rajender, primary, Pol, Stanislas, additional, Thuluvath, Paul J., additional, Kumada, Hiromitsu, additional, Toyota, Joji, additional, Chayama, Kazuaki, additional, Levin, James, additional, Lawitz, Eric J., additional, Gadano, Adrian, additional, Ghesquiere, Wayne, additional, Gerken, Guido, additional, Brunetto, Maurizia R., additional, Peng, Cheng-Yuan, additional, Silva, Marcelo, additional, Strasser, Simone I., additional, Heo, Jeong, additional, McPhee, Fiona, additional, Liu, Zhaohui, additional, Yang, Rong, additional, Linaberry, Misti, additional, and Noviello, Stephanie, additional

Published
2017
Full Text
View/download PDF

22. A randomized, controlled study of peginterferon lambda-1a/ribavirin +/- daclatasvir for hepatitis C virus genotype 2 or 3

Author

University of Helsinki, Clinicum, Foster, Graham R., Chayama, Kazuaki, Chuang, Wan-Long, Fainboim, Hugo, Farkkila, Martti, Gadano, Adrian, Gaeta, Giovanni B., Hezode, Christophe, Inada, Yukiko, Heo, Jeong, Kumada, Hiromitsu, Lu, Sheng-Nan, Marcellin, Patrick, Moreno, Christophe, Roberts, Stuart K., Strasser, Simone I., Thompson, Alexander J., Toyota, Joji, Paik, Seung Woon, Vierling, John M., Zignego, Anna L., Cohen, David, McPhee, Fiona, Wind-Rotolo, Megan, Srinivasan, Subasree, Hruska, Matthew, Myler, Heather, Portsmouth, Simon D., University of Helsinki, Clinicum, Foster, Graham R., Chayama, Kazuaki, Chuang, Wan-Long, Fainboim, Hugo, Farkkila, Martti, Gadano, Adrian, Gaeta, Giovanni B., Hezode, Christophe, Inada, Yukiko, Heo, Jeong, Kumada, Hiromitsu, Lu, Sheng-Nan, Marcellin, Patrick, Moreno, Christophe, Roberts, Stuart K., Strasser, Simone I., Thompson, Alexander J., Toyota, Joji, Paik, Seung Woon, Vierling, John M., Zignego, Anna L., Cohen, David, McPhee, Fiona, Wind-Rotolo, Megan, Srinivasan, Subasree, Hruska, Matthew, Myler, Heather, and Portsmouth, Simon D.

Abstract

Background and purpose: Peginterferon Lambda was being developed as an alternative to alfa interferon for the treatment of chronic hepatitis C virus (HCV) infection. We compared peginterferon Lambda-1a plus ribavirin (Lambda/RBV) and Lambda/RBV plus daclatasvir (DCV; pangenotypic NS5A inhibitor) with peginterferon alfa-2a plus RBV (alfa/RBV) in treatment-naive patients with HCV genotype 2 or 3 infection. Methods: In this multicenter, double-blind, phase 3 randomized controlled trial, patients were assigned 2:2:1 to receive 24 weeks of Lambda/RBV, 12 weeks of Lambda/RBV + DCV, or 24 weeks of alfa/RBV. The primary outcome measure was sustained virologic response at post-treatment Week 12 (SVR12). Results: Overall, 874 patients were treated: Lambda/RBV, n = 353; Lambda/RBV + DCV, n = 349; alfa/RBV, n = 172. Patients were 65 % white and 33 % Asian, 57 % male, with a mean age of 47 years; 52 % were infected with genotype 2 (6 % cirrhotic) and 48 % with genotype 3 (9 % cirrhotic). In the Lambda/RBV + DCV group, 83 % (95 % confidence interval [CI] 78.5, 86.5) achieved SVR12 (90 % genotype 2, 75 % genotype 3) whereas SVR12 was achieved by 68 % (95 % CI 63.1, 72.9) with Lambda/RBV (72 % genotype 2, 64 % genotype 3) and 73 % (95 % CI 66.6, 79.9) with peginterferon alfa/RBV (74 % genotype 2, 73 % genotype 3). Lambda/RBV + DCV was associated with lower incidences of flu-like symptoms, hematological abnormalities, and discontinuations due to adverse events compared with alfa/RBV. Conclusion: The 12-week regimen of Lambda/RBV + DCV was superior to peginterferon alfa/RBV in the combined population of treatment-naive patients with genotype 2 or 3 infection, with an improved tolerability and safety profile compared with alfa/RBV.

Published
2016

23. A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3

Author

Foster, Graham Russell, Heo, Jeong, Kumada, Hiromitsu, Lu, Sheng Nan, Marcellin, Patrick, Moreno, Christophe, Roberts, Stuart Keith Eith S.K., Strasser, Simone, Thompson, Alexander James V A.J., Toyota, Joji, Paik, Seung Woon, Chayama, Kazuaki, Vierling, John J.M., Zignego, Anna Linda, Cohen, David, McPhee, Fiona, Wind-Rotolo, Megan, Srinivasan, Subasree, Hruska, Matthew, Myler, Heather, Portsmouth, Simon S.D., Chuang, Wan Long, Fainboim, Hugo, Färkkilä, Martti, Gadano, Adrian, Gaeta, Giovanni Battista Attista G.B., Hezode, Christophe, Inada, Yukiko, Foster, Graham Russell, Heo, Jeong, Kumada, Hiromitsu, Lu, Sheng Nan, Marcellin, Patrick, Moreno, Christophe, Roberts, Stuart Keith Eith S.K., Strasser, Simone, Thompson, Alexander James V A.J., Toyota, Joji, Paik, Seung Woon, Chayama, Kazuaki, Vierling, John J.M., Zignego, Anna Linda, Cohen, David, McPhee, Fiona, Wind-Rotolo, Megan, Srinivasan, Subasree, Hruska, Matthew, Myler, Heather, Portsmouth, Simon S.D., Chuang, Wan Long, Fainboim, Hugo, Färkkilä, Martti, Gadano, Adrian, Gaeta, Giovanni Battista Attista G.B., Hezode, Christophe, and Inada, Yukiko

Abstract

Background and purpose: Peginterferon Lambda was being developed as an alternative to alfa interferon for the treatment of chronic hepatitis C virus (HCV) infection. We compared peginterferon Lambda-1a plus ribavirin (Lambda/RBV) and Lambda/RBV plus daclatasvir (DCV; pangenotypic NS5A inhibitor) with peginterferon alfa-2a plus RBV (alfa/RBV) in treatment-naive patients with HCV genotype 2 or 3 infection. Methods: In this multicenter, double-blind, phase 3 randomized controlled trial, patients were assigned 2:2:1 to receive 24 weeks of Lambda/RBV, 12 weeks of Lambda/RBV + DCV, or 24 weeks of alfa/RBV. The primary outcome measure was sustained virologic response at post-treatment Week 12 (SVR12). Results: Overall, 874 patients were treated: Lambda/RBV, n = 353; Lambda/RBV + DCV, n = 349; alfa/RBV, n = 172. Patients were 65 % white and 33 % Asian, 57 % male, with a mean age of 47 years; 52 % were infected with genotype 2 (6 % cirrhotic) and 48 % with genotype 3 (9 % cirrhotic). In the Lambda/RBV + DCV group, 83 % (95 % confidence interval [CI] 78.5, 86.5) achieved SVR12 (90 % genotype 2, 75 % genotype 3) whereas SVR12 was achieved by 68 % (95 % CI 63.1, 72.9) with Lambda/RBV (72 % genotype 2, 64 % genotype 3) and 73 % (95 % CI 66.6, 79.9) with peginterferon alfa/RBV (74 % genotype 2, 73 % genotype 3). Lambda/RBV + DCV was associated with lower incidences of flu-like symptoms, hematological abnormalities, and discontinuations due to adverse events compared with alfa/RBV. Conclusion: The 12-week regimen of Lambda/RBV + DCV was superior to peginterferon alfa/RBV in the combined population of treatment-naive patients with genotype 2 or 3 infection, with an improved tolerability and safety profile compared with alfa/RBV., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2016

24. A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3

Author

Foster, Graham R., primary, Chayama, Kazuaki, additional, Chuang, Wan-Long, additional, Fainboim, Hugo, additional, Farkkila, Martti, additional, Gadano, Adrian, additional, Gaeta, Giovanni B., additional, Hézode, Christophe, additional, Inada, Yukiko, additional, Heo, Jeong, additional, Kumada, Hiromitsu, additional, Lu, Sheng-Nan, additional, Marcellin, Patrick, additional, Moreno, Christophe, additional, Roberts, Stuart K., additional, Strasser, Simone I., additional, Thompson, Alexander J., additional, Toyota, Joji, additional, Paik, Seung Woon, additional, Vierling, John M., additional, Zignego, Anna L., additional, Cohen, David, additional, McPhee, Fiona, additional, Wind-Rotolo, Megan, additional, Srinivasan, Subasree, additional, Hruska, Matthew, additional, Myler, Heather, additional, and Portsmouth, Simon D., additional

Published
2016
Full Text
View/download PDF

25. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection

Author

Toyota, Joji, primary, Karino, Yoshiyasu, additional, Suzuki, Fumitaka, additional, Ikeda, Fusao, additional, Ido, Akio, additional, Tanaka, Katsuaki, additional, Takaguchi, Koichi, additional, Naganuma, Atsushi, additional, Tomita, Eiichi, additional, Chayama, Kazuaki, additional, Fujiyama, Shigetoshi, additional, Inada, Yukiko, additional, Yoshiji, Hitoshi, additional, Watanabe, Hideaki, additional, Ishikawa, Hiroki, additional, Hu, Wenhua, additional, McPhee, Fiona, additional, Linaberry, Misti, additional, Yin, Philip D., additional, Swenson, Eugene Scott, additional, and Kumada, Hiromitsu, additional

Published
2016
Full Text
View/download PDF

26. Successful achievement of sustained virological response to triple combination therapy containing simeprevir in two patients with chronic hepatitis C who had failed asunaprevir:Daclatasvir combination therapy

Author

Ozeki, Itaru, primary, Nakajima, Tomoaki, additional, Yamaguchi, Masakatsu, additional, Kimura, Mutsuumi, additional, Arakawa, Tomohiro, additional, Kuwata, Yasuaki, additional, Ohmura, Takumi, additional, Sato, Takahiro, additional, Hige, Shuhei, additional, Karino, Yoshiyasu, additional, and Toyota, Joji, additional

Published
2016
Full Text
View/download PDF

27. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis

Author

Kao, Jia‐Horng, primary, Jensen, Donald M., additional, Manns, Michael P., additional, Jacobson, Ira, additional, Kumada, Hiromitsu, additional, Toyota, Joji, additional, Heo, Jeong, additional, Yoffe, Boris, additional, Sievert, William, additional, Bessone, Fernando, additional, Peng, Cheng‐Yuan, additional, Roberts, Stuart K., additional, Lee, Youn‐Jae, additional, Bhore, Rafia, additional, Mendez, Patricia, additional, Hughes, Eric, additional, and Noviello, Stephanie, additional

Published
2016
Full Text
View/download PDF

28. Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients

Author

Kumada, Hiromitsu, primary, Suzuki, Fumitaka, additional, Suzuki, Yoshiyuki, additional, Toyota, Joji, additional, Karino, Yoshiyasu, additional, Chayama, Kazuaki, additional, Kawakami, Yoshiiku, additional, Fujiyama, Shigetoshi, additional, Ito, Takayoshi, additional, Itoh, Yoshito, additional, Tamura, Etsuko, additional, Ueki, Tomoko, additional, Ishikawa, Hiroki, additional, Hu, Wenhua, additional, McPhee, Fiona, additional, Linaberry, Misti, additional, and Hughes, Eric, additional

Published
2015
Full Text
View/download PDF

29. Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimens.

Author

Reddy, K. Rajender, Pol, Stanislas, Thuluvath, Paul J., Kumada, Hiromitsu, Toyota, Joji, Chayama, Kazuaki, Levin, James, Lawitz, Eric J., Gadano, Adrian, Ghesquiere, Wayne, Gerken, Guido, Brunetto, Maurizia R., Peng, Cheng‐yuan, Silva, Marcelo, Strasser, Simone I., Heo, Jeong, Mcphee, Fiona, Liu, Zhaohui, Yang, Rong, and Linaberry, Misti

Subjects
CLINICAL trials, HEPATITIS C virus, DRUG efficacy, INTERFERONS, LIVER cancer
Abstract

Abstract: Background & Aims: Daclatasvir has achieved high sustained virologic response (SVR) rates in diverse hepatitis C virus (HCV) populations. This study evaluated the long‐term efficacy and safety of daclatasvir‐based regimens administered during clinical studies. Methods: Patients enrolled within 6 months of parent study completion or protocol availability at the study sites. The primary objective was durability of SVR at follow‐up Week 12 (SVR12). Secondary objectives included analysing HCV sequences in non‐responders or responders who relapsed, and characterization of liver disease progression. Results: Between 24 February 2012 and 17 July 2015, this study enrolled and began following 1503 recipients of daclatasvir‐based regimens (follow‐up cut‐off, 13 October 2015); 60% were male, 18% aged ≥65 years, 87% had genotype‐1a (42%) or ‐1b (45%) infection, and 18% had cirrhosis. Median follow‐up from parent study follow‐up Week 12 was 111 (range, 11‐246) weeks. 1329/1489 evaluable patients were SVR12 responders; 1316/1329 maintained SVR until their latest visit. Twelve responders relapsed by (n = 9) or after (n = 3) parent study follow‐up Week 24; one was reinfected. Relapse occurred in 3/842 (0.4%) and 9/487 (2%) responders treated with interferon‐free or interferon‐containing regimens, respectively. Hepatic disease progression and new hepatocellular carcinoma were diagnosed in 15 and 23 patients, respectively. Among non‐responders, emergent non‐structural protein‐5A (NS5A) and ‐3 (NS3) substitutions were replaced by wild‐type sequences in 27/157 (17%) and 35/47 (74%) patients, respectively. Conclusions: SVR12 was durable in 99% of recipients of daclatasvir‐based regimens. Hepatic disease progression and new hepatocellular carcinoma were infrequent. Emergent NS5A substitutions persisted longer than NS3 substitutions among non‐responders. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

30. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey

Author

Tokushige, Katsutoshi, primary, Hyogo, Hideyuki, additional, Nakajima, Tomoaki, additional, Ono, Masafumi, additional, Kawaguchi, Takumi, additional, Honda, Koichi, additional, Eguchi, Yuichiro, additional, Nozaki, Yuichi, additional, Kawanaka, Miwa, additional, Tanaka, Saiyu, additional, Imajo, Kento, additional, Sumida, Yoshio, additional, Kamada, Yoshihiro, additional, Fujii, Hideki, additional, Suzuki, Yasuaki, additional, Kogiso, Tomomi, additional, Karino, Yoshiyasu, additional, Munekage, Kensuke, additional, Kuromatsu, Ryoko, additional, Oeda, Satoshi, additional, Yanase, Mikio, additional, Mori, Kohjiro, additional, Ogawa, Yuji, additional, Seko, Yuya, additional, Takehara, Tetsuo, additional, Itoh, Yoshito, additional, Nakajima, Atsushi, additional, Kanemasa, Kazuyuki, additional, Nishino, Ken, additional, Masaki, Naohiko, additional, Takahashi, Hirokazu, additional, Seike, Masataka, additional, Torimura, Takuji, additional, Saibara, Toshiji, additional, Toyota, Joji, additional, Chayama, Kazuaki, additional, and Hashimoto, Etsuko, additional

Published
2015
Full Text
View/download PDF

31. A case of hepatocellular carcinoma after achieving sustained virologic response treated with asunaprevir/daclatasvir in chronic hepatitis C virus infection

Author

Ozeki, Itaru, primary, Nakajima, Tomoaki, additional, Yamaguchi, Masakatsu, additional, Kimura, Mutsuumi, additional, Arakawa, Tomohiro, additional, Kuwata, Yasuaki, additional, Ohmura, Takumi, additional, Sato, Takahiro, additional, Iwaguti, Yoshihumi, additional, Gotoda, Hiroko, additional, Hige, Shuhei, additional, Karino, Yoshiyasu, additional, and Toyota, Joji, additional

Published
2015
Full Text
View/download PDF

33. Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan

Author

Kumada, Hiromitsu, primary, Sato, Ken, additional, Takehara, Tetsuo, additional, Nakamuta, Makoto, additional, Ishigami, Masatoshi, additional, Chayama, Kazuaki, additional, Toyota, Joji, additional, Suzuki, Fumitaka, additional, Nakayasu, Yoshiyuki, additional, Ochi, Miyoko, additional, Yamada, Ichimaro, additional, and Okanoue, Takeshi, additional

Published
2014
Full Text
View/download PDF

34. A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3

Author

Megan Wind-Rotolo, Adrián Gadano, Christophe Hézode, Yukiko Inada, Joji Toyota, Anna Linda Zignego, Simone I. Strasser, Giovanni Battista Gaeta, Subasree Srinivasan, Jeong Heo, Simon Portsmouth, Sheng-Nan Lu, Patrick Marcellin, Wan-Long Chuang, Heather Myler, Seung Woon Paik, David Cohen, Christophe Moreno, Hiromitsu Kumada, Alexander J. Thompson, Matthew Hruska, Graham R. Foster, Fiona McPhee, Martti Färkkilä, Hugo Fainboim, Stuart K. Roberts, Kazuaki Chayama, John M. Vierling, Foster, Graham R., Chayama, Kazuaki, Chuang, Wan Long, Fainboim, Hugo, Farkkila, Martti, Gadano, Adrian, Gaeta, Giovanni Battista, Hézode, Christophe, Inada, Yukiko, Heo, Jeong, Kumada, Hiromitsu, Lu, Sheng Nan, Marcellin, Patrick, Moreno, Christophe, Roberts, Stuart K., Strasser, Simone I., Thompson, Alexander J., Toyota, Joji, Paik, Seung Woon, Vierling, John M., Zignego, Anna L., Cohen, David, Mcphee, Fiona, Wind Rotolo, Megan, Srinivasan, Subasree, Hruska, Matthew, Myler, Heather, Portsmouth, Simon D., Clinicum, Department of Medicine, and Gastroenterologian yksikkö

Subjects
0301 basic medicine, medicine.medical_specialty, Daclatasvir, Hepatitis C virus, Peginterferon alfa-2a, Population, Peginterferon-alfa, medicine.disease_cause, THERAPY, Gastroenterology, HCV GENOTYPE-2, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, INFECTION, Genotype, medicine, PLUS SOFOSBUVIR, education, CIRRHOSIS, education.field_of_study, Multidisciplinary, business.industry, Research, Ribavirin, Peginterferon lambda-1a, virus diseases, Genotype 2, Genotype 3, Virology, digestive system diseases, 3. Good health, 030104 developmental biology, chemistry, Tolerability, 3121 General medicine, internal medicine and other clinical medicine, Technologie de la sécurité, 030211 gastroenterology & hepatology, RIBAVIRIN, Hepatitis C viru, business, medicine.drug
Abstract

Background and purpose: Peginterferon Lambda was being developed as an alternative to alfa interferon for the treatment of chronic hepatitis C virus (HCV) infection. We compared peginterferon Lambda-1a plus ribavirin (Lambda/RBV) and Lambda/RBV plus daclatasvir (DCV; pangenotypic NS5A inhibitor) with peginterferon alfa-2a plus RBV (alfa/RBV) in treatment-naive patients with HCV genotype 2 or 3 infection. Methods: In this multicenter, double-blind, phase 3 randomized controlled trial, patients were assigned 2:2:1 to receive 24 weeks of Lambda/RBV, 12 weeks of Lambda/RBV + DCV, or 24 weeks of alfa/RBV. The primary outcome measure was sustained virologic response at post-treatment Week 12 (SVR12). Results: Overall, 874 patients were treated: Lambda/RBV, n = 353; Lambda/RBV + DCV, n = 349; alfa/RBV, n = 172. Patients were 65 % white and 33 % Asian, 57 % male, with a mean age of 47 years; 52 % were infected with genotype 2 (6 % cirrhotic) and 48 % with genotype 3 (9 % cirrhotic). In the Lambda/RBV + DCV group, 83 % (95 % confidence interval [CI] 78.5, 86.5) achieved SVR12 (90 % genotype 2, 75 % genotype 3) whereas SVR12 was achieved by 68 % (95 % CI 63.1, 72.9) with Lambda/RBV (72 % genotype 2, 64 % genotype 3) and 73 % (95 % CI 66.6, 79.9) with peginterferon alfa/RBV (74 % genotype 2, 73 % genotype 3). Lambda/RBV + DCV was associated with lower incidences of flu-like symptoms, hematological abnormalities, and discontinuations due to adverse events compared with alfa/RBV. Conclusion: The 12-week regimen of Lambda/RBV + DCV was superior to peginterferon alfa/RBV in the combined population of treatment-naive patients with genotype 2 or 3 infection, with an improved tolerability and safety profile compared with alfa/RBV., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results